The Beauty Execution Reality Check

This is Part I of the Pretty Equity 2026 Execution Series — a decision report for investors and serious founders evaluating beauty businesses at moments where confidence is high, but consequences are asymmetric.

​

It is not a founder playbook. It is not a compliance checklist. It is not a substitute for formal diligence.

​

It is a pattern-based execution lens built from where beauty businesses repeatedly break once real pressure is applied.

​

• Why polish gets mistaken for preparedness—and what readiness actually looks like when it's real
• The formulation and packaging decisions that embed performance risk early
• What the FDA actually evaluates—and why having files isn't the same as being defensible
• How to qualify a contract manufacturer before you commit, not after
• The difference between QA, QC, and a quality system—and why it matters
• Why supply chain fragility is structural, not situational
• The documentation gaps that surface only when something changes
• Eight early warning signals that show up before failure becomes visible

​